Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8279917 | 1.00 | CTSB (0.37) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL3972583 | 0.96 | CTSB (0.38) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL8278248 | 0.96 | CTSB (0.38) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL8278145 | 0.93 | ADRB3 (0.39) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL3965631 | 0.93 | ADRB3 (0.39) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL8295397 | 0.93 | CTSB (0.37) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL3973101 | 0.93 | CTSB (0.37) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL8278112 | 0.93 | ADRB3 (0.42) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL3975300 | 0.93 | ADRB3 (0.42) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL8295366 | 0.92 | ADRB3 (0.38) | CTSBADRB3ADRA2BADRA2CCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6824708-B2 | SWITCHABLE BETWEEN STRONGLY AND WEAKLY SCATTERING STATES | XEROX CORPORATION | 2004-11-30 | — | — | US | claimed |
| US-20040113123-A1 | Liquid crystal compositions including dispersant | XEROX CORPORATION | 2004-06-17 | — | — | US | claimed |
| US-20090286843-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-11-19 | — | — | US | disclosed |
| US-7545557-B2 | Color display device | XEROX CORPORATION (US) | 2009-06-09 | — | — | US | disclosed |
| US-20090111969-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090111982-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090105471-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-04-23 | — | — | US | disclosed |
| US-7491794-B2 | Macrocyclic compounds as inhibitors of viral replication | INTERMUNE, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20080100906-A1 | COLOR DISPLAY DEVICE | XEROX CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| US-7282245-B2 | Device with multiple liquid crystal layers | XEROX CORPORATION (US) | 2007-10-16 | — | — | US | disclosed |
| US-7211301-B2 | Liquid crystal compositions including non-dipolar monomer | XEROX CORPORATION (US) | 2007-05-01 | — | — | US | disclosed |
| US-6767480-B2 | CONJUGATED BRIDGED ELECTRON ACCEPTOR AND DONOR MOIETIES | XEROX CORPORATION | 2004-07-27 | — | — | US | disclosed |
| EP-1439215-A1 | Domain size controlled liquid crystals | Xerox Corporation (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20040115367-A1 | Compounds of formula (2) to stabilize liquid crystal domains | XEROX CORPORATION | 2004-06-17 | — | — | US | disclosed |
| US-20040113121-A1 | COMPOUNDS OF FORMULA (1) TO STABILIZE LIQUID CRYSTAL DOMAINS | XEROX CORPORATION | 2004-06-17 | — | — | US | disclosed |
| US-20040113119-A1 | Compounds of formulas (3) and (4) to stabilize liquid crystal domains | XEROX CORPORATION | 2004-06-17 | — | — | US | disclosed |
| US-20040113123-A1 | Liquid crystal compositions including dispersant | XEROX CORPORATION | 2004-06-17 | — | — | US | disclosed |
| US-20040113122-A1 | Liquid crystal compositions including non-dipolar monomer | XEROX CORPORATION | 2004-06-17 | — | — | US | disclosed |
| US-20040115366-A1 | Domain size controlled liquid crystals | XEROX CORPORATION | 2004-06-17 | — | — | US | disclosed |
| US-20040113120-A1 | Compounds of formulas (5) and (6) to stabilize liquid crystal domains | XEROX CORPORATION | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111982-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | CTSB 1317/4885ADRB3 4337/4885ADRA2B 4492/4885 |
| US-20090286843-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | CTSB 1317/4885ADRB3 4337/4885ADRA2B 4492/4885 |
| US-20090111969-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | CTSB 1317/4885ADRB3 4337/4885ADRA2B 4492/4885 |
| US-20090105471-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | CTSB 1317/4885ADRB3 4337/4885ADRA2B 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.